{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:57:05Z","timestamp":1773392225978,"version":"3.50.1"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pemphigoid diseases, such as bullous pemphigoid and epidermolysis bullosa acquisita, are severe organ-specific autoimmune diseases characterized by subepidermal skin blistering with increasing incidence in recent years. Although there have been substantial advances in understanding the pathomechanism of these diseases in the last decades, and the first specific therapy targeting the IL-4 and IL-13 pathway (dupilumab) has been approved by the FDA for bullous pemphigoid, further research is needed to eventually improve patient care. The characteristics of pemphigoid diseases include the formation of immune complexes and their recognition by Fc\u03b3-receptors, as well as the development of a characteristic inflammatory cytokine microenvironment in the skin of the affected patients. Several non-receptor tyrosine kinases are involved in these events, playing a very important role in various signaling processes of immune cells. While certain Src-family kinases and the Syk tyrosine kinase play a very important role in signaling by Fc\u03b3-receptors, JAK-family kinases are crucial players in the signaling of various cytokine receptors including, among others, the receptors of IL-4 and IL-13. The inhibition of these tyrosine kinases with small molecule inhibitors is an emerging therapeutic option in the treatment of an increasing number of immune-mediated diseases. Moreover, numerous studies have been conducted to examine proteins (including PLC\u03b32 and CARD9) in signal transduction following Fc\u03b3-receptor activation in\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    experimental pemphigoid models, and an increasing number of case studies involving JAK inhibitors report the successful application of these drugs in various pemphigoid diseases. This review summarizes our current understanding of the therapeutically most promising tyrosine kinase signaling pathways in the pathogenesis of pemphigoid diseases.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1767876","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:49:36Z","timestamp":1773384576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tyrosine kinase signaling pathways as therapeutic targets in autoimmune subepidermal blistering skin diseases (pemphigoid diseases)"],"prefix":"10.3389","volume":"17","author":[{"given":"Simon","family":"Vik\u00e1r","sequence":"first","affiliation":[{"name":"Department of Physiology, Semmelweis University School of Medicine","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"M\u00f3csai","sequence":"additional","affiliation":[{"name":"Department of Physiology, Semmelweis University School of Medicine","place":["Budapest, Hungary"]},{"name":"HUN-REN\u2013SU Inflammation Physiology Research Group, Hungarian Research Network and Semmelweis University","place":["Budapest, Hungary"]},{"name":"MTA\u2013SE \u201cLend\u00fclet\u201d Inflammation Physiology Research Group, Hungarian Academy of Sciences and Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15046","article-title":"Autoimmune bullous dermatoses","volume":"21","author":"Holtsche","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2025.2555080","article-title":"Emerging drugs for the treatment of bullous pemphigoid: what\u2019s new on the horizon","author":"Olbrich","year":"2025","journal-title":"Expert Opin Emerg Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43556-025-00272-9","article-title":"Autoimmune bullous diseases: pathogenesis and clinical management","volume":"6","author":"Feng","year":"2025","journal-title":"Mol BioMed"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000023","article-title":"Advances in kinase inhibition: treating rheumatic diseases and beyond","volume":"26","author":"Gadina","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-12-43","article-title":"What is the future of targeted therapy in rheumatology: biologics or small molecules","volume":"12","author":"M\u00f3csai","year":"2014","journal-title":"BMC Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1084\/jem.20132496","article-title":"The Src-family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment","volume":"211","author":"Kov\u00e1cs","year":"2014","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The Syk tyrosine kinase is required for skin inflammation in an in vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"N\u00e9meth","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-genome expression profiling in skin reveals Syk as a key regulator of inflammation in experimental epidermolysis bullosa acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.12.016","article-title":"Neutrophil-specific Syk expression is crucial for skin disease in experimental epidermolysis bullosa acquisita","volume":"143","author":"N\u00e9meth","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.009","article-title":"The Syk Inhibitor entospletinib abolishes dermal-epidermal separation in a fully human ex vivo model of bullous pemphigoid","volume":"144","author":"Vik\u00e1r","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1220887","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.03.010","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"29","author":"Schmidt","year":"2011","journal-title":"Dermatol Clin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3946320241296903","DOI":"10.1177\/03946320241296903","article-title":"Association of HLA class II alleles and haplotypes with bullous and mucus membrane pemphigoid risk: A systematic review, a meta-analysis and a meta-regression","volume":"38","author":"Dhaouadi","year":"2024","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17517","article-title":"Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system","volume":"52","author":"Tan","year":"2025","journal-title":"J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils","volume":"181","author":"Forssmann","year":"2008","journal-title":"vivo. J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070498","article-title":"Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13357","article-title":"A distinct cutaneous microbiota profile in autoimmune bullous disease patients","volume":"26","author":"Miodovnik","year":"2017","journal-title":"Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104331","DOI":"10.1016\/j.yexmp.2019.104331","article-title":"Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: A pilot study","volume":"112","author":"Scaglione","year":"2020","journal-title":"Exp Mol Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700254","article-title":"Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients","volume":"126","author":"Woodley","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12507222","article-title":"An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement","volume":"78","author":"Gammon","year":"1982","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701803","article-title":"Myeloid-specific deletion of Mcl-1 yields severely neutropenic mice that survive and breed in homozygous form","volume":"201","author":"Csepregi","year":"2018","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/path.1674","article-title":"Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid","volume":"204","author":"Shimanovich","year":"2004","journal-title":"J Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.matbio.2011.09.003","article-title":"Neutrophil elastase cleaves the murine hemidesmosomal protein BP180\/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid","volume":"31","author":"Lin","year":"2012","journal-title":"Matrix Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.160.4.1027","article-title":"Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes","volume":"160","author":"Briggaman","year":"1984","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Bagci","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/biom13071019","article-title":"Eosinophils, basophils, and neutrophils in bullous pemphigoid","volume":"13","author":"Limberg","year":"2023","journal-title":"Biomolecules"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"De Graauw","year":"2017","journal-title":"Allergy"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/all.13376","article-title":"Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid","volume":"73","author":"De Graauw","year":"2018","journal-title":"Allergy"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1241461","article-title":"Monocyte populations are involved in the pathogenesis of experimental epidermolysis bullosa acquisita","volume":"14","author":"Akbarzadeh","year":"2023","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00407","article-title":"The autoimmune skin disease bullous pemphigoid: the role of mast cells in autoantibody-Induced tissue injury","volume":"9","author":"Fang","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444769","article-title":"Conditional depletion of mast cells has no impact on the severity of experimental epidermolysis bullosa acquisita","volume":"45","author":"Kasprick","year":"2015","journal-title":"Eur J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1998.39.4.339","article-title":"Complement-fixing abilities and IgG subclasses of autoantibodies in epidermolysis bullosa acquisita","volume":"39","author":"Cho","year":"1998","journal-title":"Yonsei Med J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00564.x","article-title":"Experimental models of epidermolysis bullosa acquisita","volume":"16","author":"Sitaru","year":"2007","journal-title":"Exp Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.3398","article-title":"Role of FcRs in animal model of autoimmune bullous pemphigoid","volume":"177","author":"Zhao","year":"2006","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001753","article-title":"FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid","volume":"187","author":"Messingham","year":"2011","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.010","article-title":"The role of Fc gamma receptors polymorphisms in bullous pemphigoid","volume":"63","author":"Guilabert","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/genes11040371","article-title":"A comparative analysis of CD32A and CD16A polymorphisms in relation to autoimmune responses in pemphigus diseases and subepithelial autoimmune blistering disorders","volume":"11","author":"Gornowicz-Porowska","year":"2020","journal-title":"Genes (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.037","article-title":"Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease","volume":"137","author":"Heppe","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.938306","article-title":"Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita","volume":"13","author":"Haeger","year":"2022","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.05.007","article-title":"Fc\u03b3 receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid","volume":"184","author":"Schulze","year":"2014","journal-title":"Am J Pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.230","article-title":"FcgammaRIIA and FcgammaRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid","volume":"130","author":"Yu","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.3389\/fimmu.2019.03012","article-title":"Fcgamma receptor IIB controls skin inflammation in an active model of epidermolysis bullosa acquisita","volume":"10","author":"Kovacs","year":"2019","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.02.017","article-title":"A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis","volume":"65","author":"Guilabert","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/path.6220","article-title":"Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade","volume":"262","author":"Pigors","year":"2024","journal-title":"J Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14986","article-title":"Treatment with anti-neonatal Fc receptor (FcRn. antibody ameliorates experimental epidermolysis bullosa acquisita in mice","volume":"177","author":"Kasprick","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.jid.2024.05.013","article-title":"Neonatal fc receptor inhibition reduces bullous pemphigoid anti-Basement membrane zone igG deposition and blistering in 3-Dimensional human skin equivalents","volume":"144","author":"Bao","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.2.1120","article-title":"Adhesion-dependent degranulation of neutrophils requires the Src-family kinases Fgr and Hck","volume":"162","author":"M\u00f3csai","year":"1999","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.4.669","article-title":"Fc\u03b3 receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn","volume":"191","author":"Fitzer-Attas","year":"2000","journal-title":"J Exp Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.010","article-title":"Src-family kinases: Rheostats of immune cell signaling","volume":"41","author":"Lowell","year":"2004","journal-title":"Mol Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32717-5","article-title":"Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex","volume":"269","author":"Law","year":"1994","journal-title":"J Biol Chem"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00303-5","article-title":"Syk is required for integrin signaling in neutrophils","volume":"16","author":"M\u00f3csai","year":"2002","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.7.1027","article-title":"A critical role for Syk in signal transduction and phagocytosis mediated by Fc\u03b3 receptors on macrophages","volume":"186","author":"Crowley","year":"1997","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: A crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/ni1407","article-title":"Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs","volume":"7","author":"M\u00f3csai","year":"2006","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1074-7613(00)00005-4","article-title":"Phospholipase C\u03b32 is essential in the functions of B cell and several Fc receptors","volume":"13","author":"Wang","year":"2000","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081859","article-title":"Critical role of phospholipase C\u03b32 in integrin and Fc receptor-mediated neutrophil functions and the effector phase of autoimmune arthritis","volume":"206","author":"Jakus","year":"2009","journal-title":"J Exp Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.019","article-title":"Phospholipase C\u03b32 is essential for experimental models of epidermolysis bullosa acquisita","volume":"142","author":"Szilveszter","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/ni1466","article-title":"The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors","volume":"8","author":"Hara","year":"2007","journal-title":"Nat Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"11004","DOI":"10.1038\/ncomms11004","article-title":"Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation","volume":"7","author":"N\u00e9meth","year":"2016","journal-title":"vivo. Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transd Targ Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/mi.2017.38","article-title":"Jak3 deficiency blocks innate lymphoid cell development","volume":"11","author":"Robinette","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537428","article-title":"Pemphigoid disease model systems for clinical translation","volume":"16","author":"Tigges","year":"2025","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","article-title":"Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80494-x","article-title":"Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice","volume":"5","author":"Hazenbos","year":"1996","journal-title":"Immun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80146-0","article-title":"Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects","volume":"34","author":"Schmidt","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6250","article-title":"Treatment of recurrent epidermolysis bullosa acquisita with tofacitinib","volume":"159","author":"Fan","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.06.022","article-title":"Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab","volume":"63","author":"Rasul","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2050313X231160926","DOI":"10.1177\/2050313X231160926","article-title":"A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report","volume":"11","author":"Gresham","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"110591","DOI":"10.1016\/j.intimp.2023.110591","article-title":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature","volume":"122","author":"Li","year":"2023","journal-title":"Int Immunophar"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.12144\/zgmfskin202312906","article-title":"Highly selective JAK1 inhibitor for the treatment of refractory bullous pemphigoid: a case report","volume":"39","author":"Sun","year":"2023","journal-title":"China J Leprosy Skin Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","article-title":"Two cases of bullous pemphigoid effectively treated with oral tofacitinib","volume":"32","author":"Youssef","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19475","article-title":"Abrocitinib-A promising option for patients with refractory bullous pemphigoid","volume":"38","author":"Jiang","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464474","article-title":"Treatment and molecular analysis of bullous pemphigoid with tofacitinib: a case report and review of current literature","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14345","article-title":"Successful treatment of infantile refractory bullous pemphigoid with baricitinib","volume":"65","author":"Zhou","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdcr.2024.12.017","article-title":"Bullous pemphigoid treated with baricitinib as steroid-sparing therapy for a patient with uncontrolled diabetes","volume":"57","author":"Heo","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IJDVL_300_2024","article-title":"Acute painless loss of vision due to bilateral hemiretinal vein occlusion in a case of bullous pemphigoid on tofacitinib: A potentially red flag symptom","author":"Ritu","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.511","article-title":"Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib","volume":"3","author":"Malkovics","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4103\/ds.DS-D-23-00101","article-title":"Successful treatment of bullous pemphigoid with baricitinib: A case report","volume":"41","author":"Ma","year":"2023","journal-title":"Dermatologica Sin"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1159\/000548153","article-title":"Tofacitinib for the management of coexisting pemphigoid nodularis and psoriasis: A case report and review of the literature","volume":"17","author":"Qu","year":"2025","journal-title":"Case Rep Dermatol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"37902","DOI":"10.1038\/s41598-025-21671-6","article-title":"Effectiveness and safety of methylprednisolone combination with abrocitinib compared to methylprednisolone combination with azathioprine in bullous pemphigoid: a retrospective study","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.ajoc.2021.101104","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate","volume":"27","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S451007","article-title":"Real-Time experience of abrocitinib for the treatment of mucous membrane pemphigoid: A case report","volume":"18","author":"Teng","year":"2024","journal-title":"Patient Prefer Ad"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15848","article-title":"Refractory ocular mucous membrane pemphigoid treated successfully with upadacitinib","volume":"24","author":"Maione","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtos.2025.05.002","article-title":"Janus kinase inhibitors in the treatment of refractory cicatrizing conjunctivitis in pemphigoid","volume":"38","author":"Nguyen","year":"2025","journal-title":"Ocul Surf"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16864","article-title":"Anti-laminin gamma1 (p200. pemphigoid successfully treated with tofacitinib combined with prednisone","volume":"50","author":"Zhou","year":"2023","journal-title":"J Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.29007.bfa","article-title":"Tofacitinib, a JAK1\/3 inhibitor as treatment for linear igA bullous dermatosis: A case report","volume":"34","author":"Fan","year":"2023","journal-title":"Dermatitis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf096","article-title":"Effect of upadacitinib on linear IgA bullous dermatitis complicated with ulcerative colitis exacerbated by infliximab","volume":"50","author":"Fang","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15344","article-title":"Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1\/2 inhibitor","volume":"47","author":"Moussa","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.12144\/zgmfskin202405350","article-title":"Treatment of lichen planus pemphigoid with Tofacatib: a case report","volume":"40","author":"Zhang","year":"2024","journal-title":"China J Leprosy Skin Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19440","article-title":"Rapid and sustained improvement of cutaneous lichen planus with oral JAK1 inhibitors","volume":"38","author":"Boll","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17472","article-title":"A successful experience in treating lichen planus pemphigoides with tofacitinib: a case report","volume":"64","author":"Balighi","year":"2025","journal-title":"Int J Dermatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1155\/dth\/6185003","article-title":"JAK inhibitors for pemphigoid diseases","volume":"11","author":"Sodbuyan","year":"2025","journal-title":"Dermatol Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22912","article-title":"Efficacy and safety of Bruton\u2019s tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective","volume":"9","author":"Ghane","year":"2023","journal-title":"Heliyon"},{"key":"B119","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/vde.12841","article-title":"Efficacy of a Bruton\u2019s Tyrosine Kinase Inhibitor (PRN-473). in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet Dermatol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/vde.12878","article-title":"Open trial of Bruton\u2019s tyrosine kinase inhibitor PRN1008) in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet Dermatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61317","article-title":"Pemphigus vulgaris treated with ibrutinib: A case report","volume":"16","author":"Aleissa","year":"2024","journal-title":"Cureus"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0578-17","article-title":"Paraneoplastic pemphigus associated with B-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab","volume":"57","author":"Ito","year":"2018","journal-title":"Intern Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.03.014","article-title":"Bruton\u2019s tyrosine kinase inhibition in pemphigus: an embattled frontier","volume":"144","author":"Payne","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.02.059","article-title":"Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib","volume":"56","author":"Hofmann","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13050096","article-title":"Bullous pemphigoid occurring after stopping imatinib therapy of CML: is a continuation of post-Treatment follow-Up needed","volume":"13","author":"Yakobson","year":"2023","journal-title":"Clin Pract"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1996.d01-1046.x","article-title":"Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus","volume":"135","author":"Penneys","year":"1996","journal-title":"Br J Dermatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01441.x","article-title":"Inhibition of FAK prevents blister formation in the neonatal mouse model of pemphigus vulgaris","volume":"21","author":"Gil","year":"2012","journal-title":"Exp Dermatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903101","article-title":"and Shimizu H: A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen","volume":"184","author":"Ujiie","year":"2010","journal-title":"J Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.10.002","article-title":"and Shimizu H: Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model","volume":"142","author":"Ujiie","year":"2012","journal-title":"Clin Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01720.x","article-title":"and Zillikens D: Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin","volume":"118","author":"Sitaru","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.3461","article-title":"and Zillikens D: Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice","volume":"177","author":"Sitaru","year":"2006","journal-title":"J Immunol"},{"key":"B132","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/1523-1747.ep12261694","article-title":"Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods","volume":"83","author":"Gammon","year":"1984","journal-title":". J Invest Dermatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12261694","article-title":"and Zillikens D: Autoantibodies to type VII collagen mediate Fc\u03b3-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin","volume":"161","author":"Sitaru","year":"2002","journal-title":"Am J Pathol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1087-0024.2004.00840.x","article-title":"and Meyer LJ: IgA autoimmune disorders: development of a passive transfer mouse model","volume":"9","author":"Zone","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.618","article-title":"and M\u00f3csai A: Critical but overlapping role of Fc\u03b3RIII and Fc\u03b3RIV in activation of murine neutrophils by immobilized immune complexes","volume":"180","author":"Jakus","year":"2008","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac078","article-title":"and Wang M: Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases","volume":"188","author":"Fan","year":"2023","journal-title":"Br J Dermatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2302394","article-title":"and Xie Z: Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J Dermatolog Treat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1767876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:49:39Z","timestamp":1773384579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1767876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":137,"alternative-id":["10.3389\/fimmu.2026.1767876"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1767876","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1767876"}}